The continuous progression of metabolic pharmacology has shifted from simple peptide hormone substitution to complex, multi-receptor engineering. For decades, single-target therapies dominated preclinical research, offering incremental benefits but failing to replicate the intricate, redundant feedback loops of the mammalian endocrine system.
The introduction of triple-agonist peptides has...
